BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol 2014; 20(41): 15269-15274 [PMID: 25386075 DOI: 10.3748/wjg.v20.i41.15269]
URL: https://www.wjgnet.com/1948-5182/full/v20/i41/15269.htm
Number Citing Articles
1
Dong-Mei Wu, Zi-Hui Zheng, Ying-Bo Zhang, Shao-Hua Fan, Zi-Feng Zhang, Yong-Jian Wang, Yuan-Lin Zheng, Jun Lu. RETRACTED ARTICLE: Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cellsJournal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1239-3
2
Nahla E. El-Ashmawy, Eman G. Khedr, Hoda A. El-Bahrawy, Eslam E. Abd El-Fattah. Effect of Pomegranate Hull Extract on Liver Neoplastic Changes in Rats: More than an AntioxidantNutrition and Cancer 2016; 68(6): 1044 doi: 10.1080/01635581.2016.1192205
3
Ioannis A Ziogas, Georgios Tsoulfas. Evolving role of Sorafenib in the management of hepatocellular carcinomaWorld Journal of Clinical Oncology 2017; 8(3): 203-213 doi: 10.5306/wjco.v8.i3.203
4
Inès Dufait, Els Van Valckenborgh, Eline Menu, David Escors, Mark De Ridder, Karine Breckpot. Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapyOncotarget 2106; 7(27): 42698 doi: 10.18632/oncotarget.8311
5
Ruyin Chen, Qiong Li, Shuaishuai Xu, Chanqi Ye, Tian Tian, Qi Jiang, Jianzhen Shan, Jian Ruan. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironmentCancer Cell International 2022; 22(1) doi: 10.1186/s12935-021-02435-4
6
Timothy J. Stuhlmiller, Jon S. Zawistowski, Xin Chen, Noah Sciaky, Steven P. Angus, Sean T. Hicks, Traci L. Parry, Wei Huang, Ju Youn Beak, Monte S. Willis, Gary L. Johnson, Brian C. Jensen. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor InhibitionJournal of the American Heart Association 2017; 6(10) doi: 10.1161/JAHA.117.006635
7
Huma Rafiq, Junjian Hu, Mohammed Ageeli Hakami, Ali Hazazi, Mubarak A. Alamri, Hind A. Alkhatabi, Arif Mahmood, Bader S. Alotaibi, Abdul Wadood, Xiaoyun Huang. Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulationsScientific Reports 2023; 13(1) doi: 10.1038/s41598-023-46193-x
8
Sukant Garg, Sunil Kaul, Renu Wadhwa. Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms (Review)International Journal of Oncology 2017;  doi: 10.3892/ijo.2017.4203
9
Wei Hu, Jianjun Lv, Mengzhen Han, Zhi Yang, Tian Li, Shuai Jiang, Yang Yang. STAT3: The art of multi-tasking of metabolic and immune functions in obesityProgress in Lipid Research 2018; 70: 17 doi: 10.1016/j.plipres.2018.04.002
10
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors2017; : 167 doi: 10.1016/B978-0-12-809400-6.00008-1
11
Lili Chen, Bowen Jiang, Chunge Zhong, Jun Guo, Lihao Zhang, Teng Mu, Qiuhua Zhang, Xiuli Bi. Chemoprevention of colorectal cancer by black raspberry anthocyanins involved the modulation of gut microbiota and SFRP2 demethylationCarcinogenesis 2018; 39(3): 471 doi: 10.1093/carcin/bgy009
12
Youming Ding, Xiaoyan Chen, Bin Wang, Bin Yu, Jianhui Ge. Deubiquitinase inhibitor b-AP15 activates endoplasmic reticulum (ER) stress and inhibits Wnt/Notch1 signaling pathway leading to the reduction of cell survival in hepatocellular carcinoma cellsEuropean Journal of Pharmacology 2018; 825: 10 doi: 10.1016/j.ejphar.2018.02.020
13
Yukari Mizukami, Koji Sugawara, Yukimi Kira, Daisuke Tsuruta. Sorafenib stimulates human skin type mast cell degranulation and maturationJournal of Dermatological Science 2017; 88(3): 308 doi: 10.1016/j.jdermsci.2017.08.005
14
Yide Huang, Yafei Zhang, Lilin Ge, Yao Lin, Hang Kwok. The Roles of Protein Tyrosine Phosphatases in Hepatocellular CarcinomaCancers 2018; 10(3): 82 doi: 10.3390/cancers10030082
15
You-Li Xie, Wen-Hui Tao, Ti-Xiong Yang, Jian-Guo Qiao. Anticancer effect of cucurbitacin B on MKN-45 cells via inhibition of the JAK2/STAT3 signaling pathwayExperimental and Therapeutic Medicine 2016; 12(4): 2709 doi: 10.3892/etm.2016.3670
16
Kristy J. Gotink, Maria Rovithi, Richard R. de Haas, Richard J. Honeywell, Henk Dekker, Dennis Poel, Kaamar Azijli, Godefridus J. Peters, Henk J. Broxterman, Henk M. W. Verheul. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanibCellular Oncology 2015; 38(2): 119 doi: 10.1007/s13402-015-0218-8
17
Nahla E. El-Ashmawy, Eman G. Khedr, Hoda A. El-Bahrawy, Eslam E. Abd El-Fattah. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitorClinical and Experimental Medicine 2017; 17(2): 185 doi: 10.1007/s10238-016-0416-3
18
Jianwei Wei, Zhengfeng Wang, Weiwei Wang, Xiaoge Liu, Junhu Wan, Yongjie Yuan, Xueyuan Li, Liwei Ma, Xianzhi Liu. Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF AxisFrontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.660005
19
Huimin Liu, Tianxin Du, Chen Li, Guoqing Yang. STAT3 phosphorylation in central leptin resistanceNutrition & Metabolism 2021; 18(1) doi: 10.1186/s12986-021-00569-w
20
Aliaa M. Mohassab, Heba A. Hassan, Dalia Abdelhamid, Mohamed Abdel-Aziz. STAT3 transcription factor as target for anti-cancer therapyPharmacological Reports 2020; 72(5): 1101 doi: 10.1007/s43440-020-00156-5
21
Weijia Zhao, Binglong Bai, Zhong Hong, Xuming Zhang, Bin Zhou. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma CellsACS Omega 2020; 5(38): 24838 doi: 10.1021/acsomega.0c03527
22
Ji-xiang Zhang. Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination TherapyMedical Science Monitor 2015; 21: 1781 doi: 10.12659/MSM.894669
23
Karine Breckpot. Myeloid-Derived Suppressor Cells and CancerSpringerBriefs in Immunology 2016; : 73 doi: 10.1007/978-3-319-26821-7_6
24
Andrea Lazzarini, Antonio Macchiarulo, Alessandro Floridi, Alice Coletti, Samuela Cataldi, Michela Codini, Remo Lazzarini, Elisa Bartoccini, Giacomo Cascianelli, Francesco Saverio Ambesi-Impiombato, Tommaso Beccari, Francesco Curcio, Elisabetta Albi, Patricia Bassereau. Very-long-chain fatty acid sphingomyelin in nuclear lipid microdomains of hepatocytes and hepatoma cells: can the exchange from C24:0 to C16:0 affect signal proteins and vitamin D receptor?Molecular Biology of the Cell 2015; 26(13): 2418 doi: 10.1091/mbc.e15-04-0229
25
Zhonghao Jiang, Chaoliu Dai. Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to SorafenibJournal of Hepatocellular Carcinoma 2023; : 257 doi: 10.2147/JHC.S396231